PGEN

Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.

Economic data shows mixed signals with softer-than-expected PCE inflation and stronger-than-expected Q2 GDP growth. Market attention is turning to Friday's employment report. Precigen shares surged 6.3% on growing investor confidence in sales of its FDA-approved drug Papzimeos for recurrent respiratory papillomatosis, with expected quarterly earnings up 181.8% year-over-year.

Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD) are biotech companies heavily dependent on single marketed drugs. Precigen's Papzimeos generated $74.6 million in revenues in H1 2026 with strong growth momentum and market exclusivity until 2032, while Ironwood's Linzess saw a 72.6% year-over-year profit surge. Precigen is rated as the better investment pick with a Zacks Rank #1 (Strong Buy) versus Ironwood's Rank #2 (Buy), offering clearer long-term growth prospects despite higher valuation multiples.

With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.

uniQure (QURE) announced mixed phase I/II data for its investigational gene therapy ifezuntirgene inilparvovec for Huntington's disease treatment. At 36 months, the therapy showed 80% slowing in cUHDRS and 67% in TFC versus external controls.

However, 48-month data showed weaker results with cUHDRS at 44% slowing (not statistically significant) and TFC at 61% slowing. The stock plunged 37% following the announcement. The company has submitted a BLA to the FDA based on 36-month data, with regulatory review and durability validation as key upcoming catalysts.

Iovance Biotherapeutics raised its 2026 revenue outlook to $410-$420 million from $350-$370 million, driven by strong patient demand for its therapies Amtagvi and Proleukin. The stock surged 31.5% following the announcement. Amtagvi, the first FDA-approved TIL therapy for melanoma, generated $151 million in sales in H1 2026 with 54% year-over-year growth, and the company plans to expand authorized treatment centers from 100 to at least 110 by year-end.

UroGen Pharma is transitioning from development-stage to commercial-growth biotech, driven by strong Zusduri uptake (73% sequential revenue growth to $50.4M in Q2 2026) and stable Jelmyto sales ($22M in Q2). The company's pipeline includes promising candidates like UGN-103 (94.5% response rate with NDA submitted) and UGN-104, with potential to expand beyond urothelial cancers through a strategic collaboration with IntraGel.

AbbVie announced FDA approval of Juvmo (tavapadon), a once-daily oral dopamine receptor agonist for Parkinson's disease treatment. The drug can be used alone or with levodopa and represents the first dopaminergic breakthrough for PD in decades. AbbVie expects Juvmo, along with Vyalev and Duopa, to generate over $5 billion in peak sales, strengthening its neuroscience franchise.

Mirum Pharmaceuticals announced that brelovitug met the primary endpoint in the phase III AZURE-1 study for chronic hepatitis delta virus (HDV) treatment. 56% of patients on 300 mg weekly and 45% on 900 mg every four weeks achieved virologic response and ALT normalization compared to 0% in the delayed-treatment arm.

The drug was well-tolerated with no new safety concerns. Phase III AZURE-4 data are expected in Q4 2026, with a potential BLA submission planned for H1 2027 and commercial launch expected in Q4 2027.

Acadia Pharmaceuticals received a Notice of Allowance from the USPTO that extends patent protection for trofinetide (Daybue) to March 2041, adding nearly five years to existing coverage. Daybue sales grew 25% to $226 million in H1 2026, and the drug received EU approval in August 2026, becoming the first and only approved treatment for Rett syndrome in Europe.